

10

*

10

-1

CCCCCAGCGCCCA

Met	Asp	Pro	Leu	Asn	Leu	Ser	Trp	Tyr	Asp	Asp	Leu	Glu	Arg
ATG	GAT	CCA	CTG	AAC	CTG	TCC	TGG	TAC	GAT	GAC	CTG	GAG	AGG
1									10				

Gln	Asn	Trp	Ser	Arg	Pro	Phe	Asn	Gly	Ser	Glu	Gly	Lys	Ala	Asp	30
CAG	AAC	TGG	AGC	CGG	CCC	TTC	AAT	GGG	TCA	GAA	GGG	AAG	GCA	GAC	
*				20			*								

Arg	Pro	His	Tyr	Asn	Tyr	Tyr	Ala	Met	Leu	Leu	Thr	Leu	Leu	Ile	90
AGG	CCC	CAC	TAC	AAC	TAC	TAT	GCC	ATG	CTG	CTC	ACC	CTC	CTC	ATC	

[illegible]

Arg	Glu	Lys	Ala	Leu	Gln	Thr	Thr	Thr	Asn	Tyr	Leu	Ile	Val	Ser	
GCA	GAG	AAG	GCT	TTG	CAG	ACC	ACC	ACC	AAC	TAC	TTG	ATA	GTC	AGC	70
Leu	Ala	Val	Ala	Asp	Leu	Val	Ala	Thr	Leu	Val	Met	Pro	Trp		90
CTT	GCT	GTG	GCT	GAT	CTT	CTG	GCC	ACA	CTG	GTA	ATG	CCG	TGG		270
Val	Val	Tyr	Leu	Glu	Val	Gly	Glu	Trp	Lys	Phe	Ser	Arg	Ile		
GTT	GTC	TAC	CTG	GAG	GTG	GGT	GAG	TGG	AAA	TTC	AGC	AGG	ATT		100
His	Cys	Asp	Ile	Phe	Val	Thr	Leu	Val	Met	Met	Cys	Thr	Ala		120
CAC	TGT	GAC	ATC	TTT	GTC	ACT	ACT	GTC	ATG	ATG	TGC	ACA	GCA		360
Ser	Ile	Leu	Asn	Leu	Cys	Ala	Ile	Ser	Ile	Asp	Arg	Tyr	Thr	Ala	
AGC	ATC	CTG	AAC	CTG	TGT	GCC	ATC	AGC	ATT	GAC	AGG	TAC	ACA	GCT	
Val	Ala	Met	Pro	Met	Leu	Tyr	Asn	Thr	Arg	Tyr	Ser	Ser	Lys	Arg	150
GTG	GCA	ATG	CCC	ATG	CTG	TAT	AAC	ACA	CGC	TAC	AGC	TCC	AAG	CGC	450

FIG. 1B

Arg	Val	Thr	Val	Met	Ile	Ala	Ile	Val	Trp	Val	Leu	Ser	Phe	Thr
CGA	GTT	ACT	GTC	ATG	ATT	GCC	ATT	GTC	TGG	GTC	CTG	TCC	TTC	ACC
160														
Ile	Ser	Cys	Pro	Leu	Leu	Phe	Gly	Leu	Asn	Asn	Thr	Asp	Gln	Asn
ATC	TCC	TGC	CCA	CTG	CTC	TTC	GGA	CTC	AAC	AAT	ACA	GAC	CAG	AAT
170														
Glu	Cys	Ile	Ile	Ala	Asn	Pro	Ala	Phe	Val	Val	Tyr	Ser	Ser	Ile
GAG	TGT	ATC	ATT	GCC	AAC	CCT	GCC	TTT	GTG	GTC	TAC	TCC	TCC	ATT
190														
Val	Ser	Phe	Tyr	Val	Pro	Phe	Ile	Val	Thr	Leu	Leu	Val	Tyr	Ile
GTC	TCA	TTC	TAC	GTG	CCC	TTC	ATC	GTC	ACT	CTG	CTG	GTC	TAT	ATC
200														
Lys	Ile	Tyr	Ile	Val	Leu	Arg	Lys	Arg	Arg	Lys	Arg	Val	Asn	Thr
AAA	ATC	TAC	ATC	GTC	CTC	CGG	AAG	CGC	CGG	AAG	CGG	GTC	AAC	ACC
220														
Lys	Arg	Ser	Ser	Arg	Ala	Phe	Arg	Ala	Asn	Leu	Lys	Thr	Pro	Leu
AAG	CGC	AGC	AGT	CGA	GCT	TTC	AGA	GCC	AAC	CTG	AAG	ACA	CCA	CTC
230														
240														
720														

FIG. 1C

Lys Asp Ala Ala Arg Arg Ala Gln Glu Leu	250	Glu Met Glu Met Leu
AAG GAT GCT GCC GCC CGC CGA GCT CAG GAG CTG		GAA ATG ATG ATG CTG
Ser Ser Thr Ser Pro Pro Glu Arg Thr Arg	260	Tyr Ser Pro Ile Pro
TCA AGC ACC AGC CCC CCA CAG AGG ACC CGG		TAT AGC CCC ATC CCT
Pro Ser His His Gln CAG CTC Leu Thr Act Cct	280	Pro Ser His His Gly
CCC AGT CAC CAC CAC CAG CAG CTC CTC		CCA CCA TCC CAC CAC GGC
Leu His Ser Asn Pro Pro Asp Ser Pro Ala Lys	290	Pro Gly Lys Asn Gly
CTA CAT AGC AAC AAC CCT GAC AGT CCT CCT GCC		CCA CCA GAG AAG AAT GGG
His Ala Lys Ile Val Asn Pro Arg Ile Ala	310	Lys Phe Phe Glu Ile
CAC GCC AAG ATT GTC AAT AAT CCC AGG ATT GCC		AAG AAG TTC TTT GAG ATC
Gln Thr Met Pro Asn Gly Gly Lys Thr Arg Thr	320	Ser Leu Lys Thr Met
CAG ACC ATG CCC AAT GGC GGC AAA ACC CGG ACC		TCC CTT AAG ACG ATG

FIG. 1D

Ser	Arg	Arg	Lys	Leu	Ser	Gln	Gln	Lys	Lys	Ala	Thr	Gln
AGC	CGC	AGA	AAG	CTC	TCC	CAG	CAG	AAG	AAA	GCC	ACT	CAG
Met	Leu	Ala	Ile	Val	Leu	Gly	Val	Phe	Ile	Trp	Leu	Pro
ATG	CTT	GCC	ATT	GTT	CTC	GGT	GTG	TTC	ATC	TGG	CTG	CCC
Phe	Phe	Ile	Thr	His	Ile	Leu	Asn	Ile	Cys	Asp	Asn	Ile
TTC	TTC	ATC	ACG	CAC	ATC	CTG	AAT	ATA	TGT	GAT	TGC	ATC
Pro	Pro	Val	Leu	Tyr	Ser	Ala	Phe	Thr	Trp	Tyr	Val	Asn
CCA	CCA	GTC	CTC	TAC	AGC	GCC	TTC	ACA	TGG	GTC	TAT	AAC
Ser	Ala	Val	Asn	Pro	Ile	Ile	Tyr	Thr	Thr	Ile	Glu	Phe
AGT	GCC	GTC	AAC	CCC	ATC	ATC	TAC	ACC	ACC	AAC	GAG	TTC
Arg	Lys	Ala	Phe	Met	Lys	Ile	Leu	His	Cys			
CGC	AAG	GCC	TTC	ATG	AAG	ATC	TTG	CAC	TGC	TGAGTCTGCCCCCTTGCCTG		

340 360 370 380 390 400 410 415 1170 1264

FIG. 1E

CACAGCAGCTGCTTCCCACTCCCTGCCTATGCAGGCCAGACCTCATCCCTGCAAGCTG
TGGGCAGAAAGGCCCAGATGAACCTTGGCCCTTCTCTCGACCCCTGCAGCCCTGCAGTGTTA
1383
GCTTGGCTCGATGCCCCCTCTCTGCCCACACACCCCTCATCTGCCAGGGTAGGGCCAGGG
AGACTGGTATCTTACCAGCTCTGGGGTTGGACCCATGGCTCAGGGCAGCTCACAGAGTGC
1502
CCCTCTCATATCCAGACCCCTGTCTCCTTGGCACCAAGATGCAGCGGCCCTTCCTTGACC
TTCCTCTTGGGCACAGAACTAGCTCAGTGGTCCAGCACACCCCTGATCGCTGGCTTGGCC
1621
TGGCCCTTGCTTGCCCTGTGCCGATCAGGTGGTGGGAGGGAGCGACACGTTCTTACTTT
ATAGGAACCACATAGGAAAGCAGGGAACACGCCCAAGTCCTCCAGGCACATCAGTGTGAGG
1740
AGACACACATAAACACCAGGTAGCTCCATGGACCCCAAGAACTGAGGCTGAAAAATC
TGTTTTCCACTCCAACCTAGTGTGAGTCCCTACTTTTCATAGCCATGGGTATTACTATG
1859

FIG. 1F

TCCTACCTTGTTATAGTATCCCATGGGGTTTCTGTACCATTTGGGGGAAACAACACTCTA
 ATCCTCAAGGGCCCAAGAGAACTCTGTAGGAGAAAAATAGGCTGATCTCCCTCTACTCT
 CCAATCCACTCCACCACCTTCTTGATATACCTTGGATGTATCCATTCCCTCACAGCAAATG
 CTGGCCAGTCAGGCCTTGGACCAGTGTGGAGTTGAAGCTGGATGTGGTAACTTGGGGCT
 CTTGGGGCTGGGGGGTGTAAACATCGTCTCTCTTCCATATCTCTTCCCTTCCCAGTG
 CCTCTGCCCTTAGAAGAGGCTGTGGATGGGGTGCTGGGACTGCTGATACCATTTGGGCTGG
 CCCTGAATGAGGAGGGAAGCTGCAGTTTGGAGGTTCTGGGATCCAACTCTGTAAACAT
 CACTATACCTGTACCAAACTAATAAACCTTGACAAGAGTCAAAAA
 2317

FIG. 1G

D₆
β₆
α₆
G-21
M₁
SK

I
MD... PL... NISWYDDLLERQNSRPFNGSEKADRPYNYAMITLL. IFIIVFGNVLVCMVAVSREKALQITITNY
MGP... P... QNDSDFLLTNGSHV... PDHVDTEERDEAVVVGMAIMSVIVLAVFGNVLVITAIKAFERLOITVINY
MGSLLQ. POA. QNASWNGTEAPG... GGRATPYSLQVT... LTLVCLAGLL. MLLTVFGNVLVITAVFTSRATKAPQNL
MDVLS. PQG. QNNTSPPAPFE... TGCNTTGISDVTVSQV. ITSLLIGTLL. IFCAVTCNAGVAVAIALERSLQNVANY
MNTSAPPAVSPNITVLAP... GKGWQVA... FIGITITGLL. SLATVTCNLTLLVTSFKVNTETKTVNY
MGACV. VMTDINIS. SGLDSNATGITAFSMPGWQLALWTAAYLAL. VLVAVMGNATVWIIILAHQRMRTVINY

D₆
β₆
α₆
G-21
M₁
SK

II
LIVSLAMADITIVATLVMPWVVYLEVQVMSFRIHCDIFVTLDMCTASILNLCASIQRYTAVAMPMTIMTRYSSKPR
FIVSLACADIVMGIAVMPFGASHIIMQWVNFNFWCEFWTSIQVLCVTASIEITLCVIAVQRYVIAITSEFKYQSLITKNKA
FIVSLASADILVATLVMPFSLANEMQWVMECKTWCEIYALDVLCTSSIVHLCAISIQRYWSTQAIETINLKRTPRPI
LIGSLAVTDMVSVLVITVMAALYQMLNNWTLQVTCDFIALDVLCTSSILHLCAIAIQRYWSTQAIETINLKRTPRPI
FLLSLACADILIIIGFISNLYTTLIMQWVMAIGTLACDLWLALDVASNA SUMNLLISFQRYFSVTRPLSYRAKTRPRRA
FIVNLALADICMAAFNAFVYASHNIMVYEGRAFCKYQNLFPITAMFVSIYSMTAIAAQRYMAIVRPFQRLSAPGTR.

D₆
β₆
α₆
G-21
M₁
SK

IV
VTMTIAIVWVISETISC. PLLFLGLNNTD... QNECIANPAFVVYSSIMSYVVPFLVILLVYIKIVILVRKRKRQVNTKR--(111)
RMV. IILMVWIVSGLTSEFPIQMHWYRATH... QKAIDCYHRETCCDFFTNQAYATWSSIVSYVVPFLVILLVYIKIVILVRKRKRQVNTKR--(111)
KAI. IITVWVISAVIDSEFPLISIEKKGG... GGPQPAEPRCEINDQKVVVSSCIGSFAPQIIMLVVWVRIYQIAKRTRVP--(137)
ALT. SLT. MLIGLISIPMLGWRTPEDR... SDPDACTISKDMGYTIVSTFGAFYIPILMLVLYGRIFRAARFIPIT--(110)
ALM. IGLAWLVSEVLWA. PAILFWQYLVE... RTVLACQCYIQFLSQPIITFGTAMAAFYLPVTMCTIYWRIYRETNAREL--(137)
.AV. IAGIELVALALAF. PQCFYSTITDEGATKCVVWAPEDSGGKMLLYHLIVIALIYE. LPQVWVAVSVIGLTLWRSVPG--(12)--

D₆
β₆
α₆
G-21
M₁
SK

VII
-KEKKAITQMTAIVIGMFTHCWLPPFFITHIINIHCOCN... IPVLYSAFTWLGYNVSA... VNPITITTEFENAFKILH
-KEKKAITQMTAIVIGMFTHCWLPPFFITHIINIHCOCN... IPVLYSAFTWLGYNVSA... VNPITITTEFENAFKILH
-REKRTFVIAVIGMFTHCWLPPFFITHIINIHCOCN... IPVLYSAFTWLGYNVSA... VNPITITTEFENAFKILH
-REKRTVKTQIMGIFILCWIPFFITHIINIHCOCN... IPVLYSAFTWLGYNVSA... VNPITITTEFENAFKILH
-KEKKAARTSAILLAFIVMIVNIMVLVSTFCDC... VETITWELGYWIGYNVST... INPMGYALQNKAFRDTFRLLHCR--(24)
-AKKVFVKTMVIVVTEFAICWLPYHLYFIIGTFQEDIYCHKFIQVYLALPWA... MSTMNPIIYCCINHRFSQERLAPRCC--(62)




FIG.4A-1





FIG.4A-2


FIG. 4B




DRUG		Ki (nM)	
		Transformed Ltk-Cells	Rat Striatum
RGB-2			
(+)-Butaclamol	0.83	1.0	
(-)-Butaclamol	>1,000	>1,000	
Haloperidol	3.0	5.3	
Dopamine + GTP	17,000	6,300	
Sulpiride	80	67	(87%)
high affinity	---	>10,000	(13%)
low affinity			
SCH 23390	---	35	(16%)
high affinity	1,000	780	(84%)
low affinity			
Ketanserin	---	27	(25%)
high affinity	>1,000	>1,000	(75%)
low affinity			

FIG. 4C

TOP SECRET



RGB-2






FIG. 6B




FIG. 6C




FIG. 6E

FIG. 7A

3' GTC GGG TGG GCT CTC CTG GGC CAT GTC GGG GTA GGG TGG GTC GGT GGT GGT CGA 54
 5' CAG CCC ACC CGA GAG GAC CCG GTA CAG CCC CAT CCC ACC CAG CCA CCA CCA GCT 54
 Gln Pro Thr Arg Glu Asp Pro Val Gln Pro His Pro Thr Gln Pro Pro Pro Pro Ala
 Ser Pro Pro Glu Arg Thr Arg Tyr Ser Pro Ile Pro Pro Ser His His Gln Leu
 Ala His Pro Arg Gly Pro Gly Thr Ala Pro Ser His Pro Ala Thr Thr Ser

81
 CTG AGA GGG GCT GGG CAG GGT GGT ACC AGA GGT GTC GTG AGG GCT GTC GGT GGT GGT 108
 GAC TCT CCC CGA CCC GTC CCA CCA TGG TCT CCA CAG CAC TCC CGA CAG CCC CGC
 Asp Ser Pro Arg Pro Val Pro Pro Trp Ser Pro Gln His Ser Arg Gln Pro Arg
 Thr Leu Pro Asp Pro Ser His His Gly Leu His Ser Thr Pro Asp Ser Pro Ala
 Leu Ser Pro Thr Arg Pro Thr MET Val Ser Thr Ala Leu Pro Thr Ala Pro Pro

135
 GTT TGG TCT CTT CTT ACC CGT ACC GGT TTC CTG GTG GGG TTC CTA ACG GTT CTA 162
 CAA ACC AGA GAA GAA TGG GCA TGC CAA AAG GAC CAC CCC AAG GAT TGC CAA GAT
 Gln Thr Arg Glu Glu Trp Ala Cys Gln Lys Asp His Pro Lys Asp Cys Gln Asp
 Lys Pro Glu Lys Asn Gly His Ala Lys Arg Thr Thr Pro Arg Ile Ala Lys Ile
 Asn Gln Arg Arg MET Gly MET Pro Lys Gly Pro Pro Gln Gly Leu Pro Arg Ser

189
 GAA ACT CTA GGT CTG GTA CCG GTT ACC GTT TTG GGC CTG GAG GGA GTT CTG GTA 216
 CTT TGA GAT CCA GAC CAT GCC CAA TGG CAA AAC CCG GAC CTC CCT CAA GAC CAT
 Leu . Asp Pro Asp His Ala Gln Trp Gln Asn Pro Asp Leu Pro Gln Asp His
 Phe Glu Ile Gln Thr MET Pro Asn Gly Lys Thr Arg Thr Ser Leu Lys Thr MET

FIG. 7B

CTC GGC ATC CTT C6A G55 GGT CGT CTT CCT CTT TCG GTG AGT CTA CGA GCG 270
GAG CCG TAG GAA G3T C44 CCA GCA GAA GGA GAA AGC CAC TCA GAT GCT CGC
Glu Pro . Glu C TT Pro Ala Glu Gly Glu Ser His Ser Asp Ala Arg
Ser Arg Arg Lys Leu Phe Gln Gln Lys Glu Lys Ala Thr Gln MET Leu Ala
Ala Val Gly Ser Ser Arg Arg Arg Lys Pro Leu Arg Cys Ser Pro

243

GTA 5CA AGA GCC GCA CAA GTA GTA GAC CGA CGG GAA GAA GTA GTG TGT GTA 324
CAT 4GT TCT CCG CGT GTT CAT CAT CTG CTG GCT GCC CTT CTT CAT CAC ACA CAT
His T Ser Arg Arg Val His His Leu Ala Ala Leu Leu His His Thr His
ILE Val Leu Gly Val Phe Ile Ile Cys Trp Leu Pro Phe Phe Ile Thr His Ile
le Phe Ser Ala Cys Ser Ser Ser Ala Gly Cys Pro Ser Ser His Thr Ser

297

GGA CTT GTA TGT GAC ACT GAC GAC GGT GAC GGG CGG ACA GGA CAT GTC GCG GAA GTG 378
CCT GAA CAT ACA CTG TGA CTG CAA CAT CCC GCC TGT CCT GTA CAG CGC CTT CAC
Pro Glu His Thr Leu . Leu Gln His Pro Ala Cys Pro Val Gln Arg Leu His
Leu Asn Ile His Cys Asp Cys Asn Ile Pro Pro Val Leu Tyr Ser Ala Phe Thr
. Thr Tyr Thr Val Thr Ala Thr Ser Arg Leu Ser Cys Thr Ala Pro Ser Arg

351

CAC CGA CCC GAT ACA GTT GTC GCG GCA CTT GGG GTA GTA GAT GTG GTG GAA GTT 432
GTG GCT GGG CTA TGT CAA CAG CGC CGT GAA CCC CAT CAT CTA CAC CAC CTT CAA
Val Ala Gly Leu Cys Gln Gln Arg Arg Glu Pro His His Leu His His Leu Gln
Trp Leu Gly Tyr Val Asn Ser Ala Val Asn Pro Ile Ile Tyr Thr Thr Phe Asn
Gly Trp Ala MET Ser Thr Ala Pro . Thr Pro Ser Ser Thr Pro Pro Ser Thr

405

459
 GTA ACT CAA GGC GTT CCG GAA GGA CTT CTA GGA GGT GAC GAC TGA GAC GAC GAC 486
 CAT TGA GTT CCG CAA GGC CTT CCT GAA GAT CCT CCA CTG CTG ACT CTG CTG GGA
 His Val Pro Gln Gly Leu Pro Glu Asp Pro Leu Leu Thr Leu Leu Pro
 Ile Glu Phe Arg Lys Ala Phe Leu Lys Ile Leu His Cys STOPLeu Cys Cys Leu
 Leu Ser Ser Ala Arg Pro Ser Arg Ser Ser Thr Ala Asp Ser Ala Ala Cys

513
 CGG CGT GTC GTC GGA CGA AGG GTG CAG GGA CGG GTC ACG GCC GGT CGG AGT GGG 540
 GCC GCA CAG CAG CCT GCT TCC CAC CTC CCT GGC CAG TGC CGG CCA GCC TCA CCC
 Ala Ala Gln Gln Pro Ala Ser His Leu Pro Ala Gln Cys Arg Pro Ala Ser Pro
 Pro His Ser Ser Leu Leu Pro Thr Ser Leu Pro Ser Ala Gly Gln Pro His Pro
 Arg Thr Ala Ala Cys Phe Pro Pro Cys Pro Val Pro Ala Ser Leu Thr Leu

567
 AAC GCT TGG CAC TCG TCC TTC CCG ACC CAC CTA GCC GGA GAA GAT CGG GGC 594
 TTG CGA ACC GTG AGC AGG AAG GCC TGG GTG GAT CGG CCT CCT CTT CTA GCC CCG
 Leu Arg Thr Val Ser Arg Lys Ala Trp Val Asp Arg Pro Pro Leu Leu Ala Pro
 Cys Glu Pro Ala Gly Arg Pro Gly Trp Ile Gly Leu Leu Phe Pro Arg
 Ala Asn Arg Glu Gln Glu Gly Leu Gly Ser Ala Ser Ser Ser Ser Pro Gly

FIG. 7C




FIG. 8




FIG. 9A





FIG. 9B






FIG. 10A




FIG. 10B

CONTROL

		+P.T.			
BASAL	FSK	FSK+DA	BASAL	FSK	FSK+DA
2.1	22.6	14.3	1.7	26.7	23.1
0.2	2.2	2.1	0.4	2.0	0.5
—	—	41%	—	—	14%

\bar{X}
S.E.

FIG. 12A

INH

CONTROL

+P.T.									
BASAL		VIP	DA	VIP+DA		BASAL	VIP	DA	VIP+DA
0.60		2.41	0.32	0.84		0.61	2.68	0.55	2.56
0.02		0.31	0.02	0.13		0.09	0.08	0.03	0.25
—		—	53%	71%		—	—	10%	3%

\bar{X}
S.E.

FIG. 12B

INH

CONTROL

+P.I.											
BASAL		VIP	DA	VIP+DA		BASAL		VIP	DA	VIP+DA	
0.78		5.1	0.25	0.76		0.64		5.29	0.66	4.76	
0.04		0.4	0.03	0.01		0.01		0.44	0.03	0.16	
—		—	68%	88%		—		—	0%	12%	

\bar{X}
S.E.

FIG. 12C

INH

FIG. 13B-1




FIG. 13B-2




FIG. 13C





FIG. 14C

D

D(-S)





[illegible]

FIG. 14B








FIG.17A





FIG.17B



-33 AGAGCTGGCCACCCAGTGGCTCCACCGCCCTG

	*	10	*	20
METAspProLeuAsnLeuSerTrpTyrAspAspLeuGluArgGlnAsnTrpSerArg
ATGGATCCACTGAATCTGTCTCGTATGATGATCTGCAGAGGCAGAACTGGAGCCGG
ATGGATCCACTGAACCTGTCTCGTACGATGACGATCTGGAGAGGCAGAACTGGAGCCGG

*
ProPheAsnGlySerAspGlyLysAlaAspArgProHisTyrAsnTyrTyrAlaThrLeu
30 40
CCCTTCAACGGGTCAGACGGGAAGCGGCAGACCCCACTAACA·
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
CCCTTCAATGGGTCAGAAAGGAAGGCAGACAGCCCACTA·
Glu
CACTACTATGCCATGCTG
MET

FIG. 18A

120

1

50

60

LeuThrLeuLeuIleAlaValIleValPheGlyAsnValLeuValCysMETAlaValSer

CTCACCCCTGCTCATCGTCTCTTCGGCAACGTGCTGGTGTGCATGGCTGTGTCC

||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

CTCACCCCTCATCTTATCATCGTCTTTGGCAATGTGCTGGTGTGCATGGCTGTATCC

PheIle

70

80

ArgGluLysAlaLeuGlnThrThrThrAsnTyrLeuIleValSerLeuAlaValAlaAsp

CGCGAGAAGCGCTGCAGACCAACCACTACCTGATCGTCAGCCCTCGCAGTGGCCGAC

|| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

CGAGAGAAGGCTTTCAGACCAACCACTACTTGATAGTCAGCCTTGCTGTGGCTGAT

240

90

100

LeuLeuValAlaThrLeuValMETProTrpValValTyrLeuGluValValGlyGluTrp

CTCCTCGTCGCCACACTGGTCAATGCCCTGGGTTGTCTACCTGGAGGTGGTAGGTAGTGG

|| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

CTTCTGGTGGCCACACTGGTAATGCCGTGGGTTGTCTACCTGGAGGTGGTGGGTAGTGG

IV

ValLeuSerPheThrIleSerCysProLeuLeuPheGlyLeuAsnAsnAlaAspGlnAsn 170 180
 GTCCTGTCCTTCACCATCTCCTGCCCACTCCTCTTCGGACTCAATAACGCAGACCAGAAC
 !!!!!!!
 GTCCTGTCCTTCACCATCTCCTGCCCACTGCTCTTCGGACTCAACAATACAGACCAGAAT
 Thr

GluCysIleIleAlaAsnProAlaPheValValTyrSerSerIleValSerPheTyrVal 190 200
 V
 GAGTGCATCATTGCCAAACCCGGCCTTCGTGGTCTACTCCTCCATCGTCTCCTTCTACGTG
 !!!!!!!
 GAGTGTATCATTGCCAAACCCCTTGTGGTCTACTCCTCCATTGTCTCATTTCTACGTG 600

ProPheIleValThrLeuLeuValTyrIleLysIleTyrIleValLeuArgArgArg 210 220
 CCCCTTCATTGTCACCCCTGCTGGTCTACATCAAGATCTACATTGTCCCTCCGCAGACGCCGC
 !!!!!!!
 CCCCTTCATCGTCACTGCTGCTATATCAAAATCTACATCGTCCCTCCGGAAGCCCGG
 Lys

FIG. 18D

LysArgValAsnThrLysArgSerArgAlaPheArgAlaHisLeuArgAlaProLeu 230 240
 AAGCGAGTCAACACCAACGAGCAGCCGAGCTTTCAGGGCCACCTGAGGGCTCCACTA
 !!!!! !!!!! !!!!! !!!!! !!!!! !!!!! !!!!! !!!!! !!!!! !!!!! 720
 AAGCGGTCAACACCAAGCGCAGCAGTCGAGCTTTCAGAGCCAACTGAAGACACCACTC
 Asn LysThr
 * 250 *
 LysGlyAsnCysThrHisProGluAspMETLysLeuCysThrValIleMETLysSerAsn
 ▼ AAGGGCAACTGTACTCACCCTCGAGGACATGAAACTCTGCACCGTTATCATGAAGTCTAAT
 !!!
 AAG.....
 GlySerPheProValAsnArgArgArgValGluAlaAlaArgArgAlaGlnGluLeuGlu 270 280
 GGGAGTTTCCCAGTGAACACGCGGAGAGTGGAGGCTGCCCCGGCGAGCCCAGGAGCTGGAG
 !! !!!!! !!!!! !!!!! !!!!! !!!!! !!!!! !!!!! !!!!! !!!!!
GATGCTGCCCGCGGAGCTCAGGAGCTGGAA 840
 Asp

FIG. 18E

290 300
 METGluMETLeuSerSerThrSerProProGluArgThrArgTyrSerProIleProPro
 ATGGAGATGCTCTCCAGCACCAAGCCACCCGAGAGAGACCCGGTACAGCCCCCATCCCCACCC
 IIIIIIIIIII IIIIIIIIIII IIIIIIIIIII IIIIIIIIIII IIIIIIIIIII III
 ATGGAGATGCTGTCAAGCACCAAGCCCCAGAGAGAGAGACCCGGTATAGCCCCCATCCCCCTCCC

310 320
 SerHisHisGlnLeuThrLeuProAspProSerHisHisGlyLeuHisSerThrProAsp
 AGCCACCACCAAGCTGACTCTCCCCGACCCGTCCTCCACCATGGTCTCCACAGCACTCCCGAC
 IIIIIIIIIII IIIIIIIIIII IIIIIIIIIII IIIIIIIIIII IIIIIIIIIII III
 AGTCACCACCAAGCTCACTCTCCCTGATCCATCCACCAAGGCGCTACATAGCAACCCCTGAC
 Asn 960

330 339
 SerProAlaLysProGluLysAsnGlyHisAlaLys AspHisProLysIleAlaLys
 AGCCCCGCCAAACCAAGAGAAATGGGCATGCCAAA...GACCAACCCCAAGATTGCCAAG
 IIIIIIIIIII IIIIIIIIIII IIIIIIIIIII IIIIIIIIIII IIIIIIIIIII III
 AGTCCTGCCAAACCAAGAGAAATGGGCACGCCAAGATTGTCAATCCCAGGATTGCCAAG
 IleValAsn Arg

FIG. 18F

IlePheGluIleGlnThrMETProAsnGlyLysThrArgThrSerLeuLysThrMETSer
 ATCTTTGAGATCCAGACCATGCCCAATGGCAAACCCGGACCTCCCTCAAGACCATGAGC
 TTTCTTTGAGATCCAGACCATGCCCAATGGCAAACCCGGACCTCCCTTAAGACCATGAGC
 Phe

[illegible]

VI

389

GlyValPheIleIleCysTr0LeuProPhePheIleThrHisIleLeuAsnIleHisCys

399

GGCGTGTTCATCTGCTGGCTGCCCTTCTTCATCACACACATCCTGAACATACACTGT

II IIIIIIIIIIIIIIIIIIIIIIIIIIIIIII IIIIIIIII

GCCGTCAACCCCATCATCTACACACCACCTTCAACATCGAGTCCGCAAGGCCTTCATGAAG

MET

FIG 100

FIG. 18G

CAGGCCGCCAGCCTCACCCCTTGCGAACCGTGAGCAGGAAGGCCCTGGGTGGATCGGCCTC 1437

CTCTTCTAGCCCGGCAAGGCCCTGCAGTGTTCGCTTGGCTCCATGCTCCTCACTGCCCG

CACACCTCACTCTGCCAGGCAGTGCTAGTGAGCTGGGCATGGTACCAGCCCTGGGGCT 1557

GGCCCAGCTCAGGGCAGCTC[.]ATAGAGTCCC[.]CCCTCCCACCTCCAGTCCCC[.]CCCTATCCCTT

GGACCAAGATGCAGCGCCTTCCTTGACCTTCCTCTGGGGCTCTAGGTTGCTGGAGC 1677

CTGAGTCAGGGCCAGAGGCTGAGCTTTCTCTTTGTGGGCTTGGCGTGGAGCAGCGCGT

GGGAGAGATGGACAGTTCACACCTGCAAGGCCACAGGCCAAGCCTCTCTGC 1797

CGAGGAGCCAGGCAACTTCAGTCTGGGAGACCCATGTAAATACCAGACTGCAGGTTGGA

CCC AAGGATTC CCAAGCCAAAACCTTAGCTCCCTCCCGCACCCCGATGTGGACCTCTA 1917


FIG. 181

CTTCCAGGCTAGTCCGGACCCACCTCACCCCGTTACAGCTCCCCAAGTGGTTTCCACAT
GCTCTGAGAAAGAGGCCCTCATCTTGAAGGCCCCAGGAGGTCTATGGGAGAGGAACT 2037
CCTTGGCCTAGCCACCCCTGCTGCCCTTCTGACGGCCCTGCAATGTATCCCTTCTCACAGC
ACATGCTGGCCAGCCTGGGGCCTGGCAGGGAGGTCAGGCCCTGGAACTCTATCTGGGCCT 2157
GGGCTAGGACATCAGAGGTTCTTTGAGGGACTGCCCTCTGCCACACTCTGACGCAAAACC
ACTTCCCTTTTCTATTCCCTTCTGGCCTTTCCCTCTCTCCTGTCTCCCTTCCCTTCCACTGC 2277
CTCTGCCCTTAGAGGAGCCACGGCTAAGAGGCTGCTGAAACCATCTGGCCTGGCCTGGC
CCTGCCCTGAGGAAGGAGGGCAAGCTGCAGCTTGGGAGAGCCCCTGGGCCTAGACTCTG 2397
TAACATCACTATCCGATGCACCAAACTAATAAACTTTGACGAGTCACCTTC (A)_n 2449

FIG. 18J

- ◇ SPIPERONE
- (+)BUTACLAMOL
- HALOPERIDOL
- ▲ SULPIRIDE
- MIANSERIN
- △ SCH-23390
- (-)BUTACLAMOL

FIG. 19



1 2 3 4

kb

—12.0

— 6.0

— 4.0


— 2.0

— 1.6

— 1.0

FIG. 20

FIG. 21



DRUG	HUMAN D ₂	RAT D ₂	RAT STRIATUM
SPIPERONE	0.125	0.35	0.56
(+) BUTACLAMOL	0.94	1.2	1.6
HALOPERIDOL	2.4	5.1	5.8
SULPIRIDE	206	160	205
MIANSERIN (5-HT)	2685	4300	4600
SCH 23390 (DI)	2145	2500	3300
(+) BUTACLAMOL	>10,000	>10,000	>10,000
Kd [³ H] DOMPERIDONE	0.74	0.40	0.40

FIG. 22

FIG. 23

2851	286
exon1...GGA [.] Gtagtg...	intr [.] on1...tccccagGTGG...exon2
395	396
exon2...ACA [.] Ggtgagcc...	intr [.] on2...cttgcagGTAC...exon3
532	533
exon3...GCA [.] Ggtacatt...	intr [.] on3...ccccccagACCA...exon4
723	724
exon4...AAA [.] Ggtctcaa...	intr [.] on4...tccacagGGCA...exon5
810	811
exon5...AGT [.] Ggtaagt...	intr [.] on5...gggtcagGAGG...exon6
1138	1139
exon6...CTC [.] Ggtgagtc...	intr [.] on6...ccccccagGCGT...exon7

¹Numbering begins with A of the putative initiator methionine codon (see Fig. 18)